![](/img/cover-not-exists.png)
Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer
Raghunadharao, D, Wilhelm, FE, Acharya, M, Advani, SH, Achrekar, SD, Doval, DCVolume:
51
Year:
2014
Language:
english
Journal:
Indian Journal of Cancer
DOI:
10.4103/0019-509X.134617
File:
PDF, 513 KB
english, 2014